1887

Journal of General Virology header logo

Volume 97, Issue 1

Adenovirus hexon modifications influence properties of pseudotyped human adenovirus type 5 vectors Free

Abstract

Commonly used human adenovirus (HAdV)-5-based vectors are restricted by their tropism and pre-existing immunity. Here, we characterized novel HAdV-5 vectors pseudotyped with hypervariable regions (HVRs) and surface domains (SDs) of other HAdV types. Hexon-modified HAdV-5 vectors (HV-HVR5, HV-HVR12, HV-SD12 and HV-SD4) could be reconstituted and amplified in human embryonic kidney cells. After infection of various cell lines, we measured transgene expression levels by performing luciferase reporter assays or coagulation factor IX (FIX) ELISA. Dose-dependent studies revealed that luciferase expression levels were comparable for HV-HVR5, HV-SD12 and HV-SD4, whereas HV-HVR12 expression levels were significantly lower. Vector genome copy numbers (VCNs) from genomic DNA and nuclear extracts were then determined by quantitative real-time PCR. Surprisingly, determination of cell- and nuclear fraction-associated VCNs revealed increased VCNs for HV-HVR12 compared with HV-SD12 and HV-HVR5. Increased nuclear fraction-associated HV-HVR12 DNA molecules and decreased transgene expression levels were independent of the cell line used, and we observed the same effect for a hexon-modified high-capacity adenoviral vector encoding canine FIX. In conclusion, studying hexon-modified adenoviruses demonstrated that HVRs but also flanking hexon regions influence uptake and transgene expression of adenoviral vectors.

  • Received:
  • Accepted:
  • Published Online:
© 2015
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000328
2016-01-01
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/1/160.html?itemId=/content/journal/jgv/10.1099/jgv.0.000328&mimeType=html&fmt=ahah

References

  1. Alba R., Bradshaw A. C., Parker A. L., Bhella D., Waddington S. N., Nicklin S. A., van Rooijen N., Custers J., Goudsmit J., other authors. 2009; Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114:965–971 [View Article][PubMed]
     [Google Scholar]
  2. Amicone L., Spagnoli F. M., Späth G., Giordano S., Tommasini C., Bernardini S., De Luca V., Della Rocca C., Weiss M. C., other authors. 1997; Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes. EMBO J 16:495–503 [View Article][PubMed]
     [Google Scholar]
  3. Bradshaw A. C., Coughlan L., Miller A. M., Alba R., van Rooijen N., Nicklin S. A., Baker A. H. 2012; Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses. J Control Release 164:394–402 [View Article][PubMed]
     [Google Scholar]
  4. Bruder J. T., Chen P., Semenova E., Thomas C. A., Konovalova S., Ekberg G., Ettyreddy D., McVey D., Gall J. G., other authors. 2013; Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors. J Virol 87:9661–9671 [View Article][PubMed]
     [Google Scholar]
  5. Cassany A., Ragues J., Guan T., Bégu D., Wodrich H., Kann M., Nemerow G. R., Gerace L. 2015; Nuclear import of adenovirus DNA involves direct interaction of hexon with an N-terminal domain of the nucleoporin Nup214. J Virol 89:1719–1730 [View Article][PubMed]
     [Google Scholar]
  6. Coughlan L., Bradshaw A. C., Parker A. L., Robinson H., White K., Custers J., Goudsmit J., Van Roijen N., Barouch D. H., other authors. 2012; Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 20:2268–2281 [CrossRef]
     [Google Scholar]
  7. Crawford-Miksza L., Schnurr D. P. 1996; Analysis of 15 adenovirus hexon proteins reveals the location and structure of seven hypervariable regions containing serotype-specific residues. J Virol 70:1836–1844[PubMed]
     [Google Scholar]
  8. Doronin K., Flatt J. W., Di Paolo N. C., Khare R., Kalyuzhniy O., Acchione M., Sumida J. P., Ohto U., Shimizu T., other authors. 2012; Coagulation factor X activates innate immunity to human species C adenovirus. Science 338:795–798 [View Article][PubMed]
     [Google Scholar]
  9. Ebner K., Pinsker W., Lion T. 2005; Comparative sequence analysis of the hexon gene in the entire spectrum of human adenovirus serotypes: phylogenetic, taxonomic, and clinical implications. J Virol 79:12635–12642 [View Article][PubMed]
     [Google Scholar]
  10. Gahéry-Ségard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J.-G. 1998; Immune response to recombinant capsid proteins of adenovirus in humans: antifibre and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 72:2388–2397[PubMed]
     [Google Scholar]
  11. Gall J. G. D., Crystal R. G., Falck-Pedersen E. 1998; Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype. J Virol 72:10260–10264[PubMed]
     [Google Scholar]
  12. Gallaher S. D., Berk A. J. 2013; A rapid Q-PCR titration protocol for adenovirus and helper-dependent adenovirus vectors that produces biologically relevant results. J Virol Methods 192:28–38 [View Article][PubMed]
     [Google Scholar]
  13. Hausl M. A., Zhang W., Muther N., Rauschhuber C., Franck H. G., Merricks E. P., Nichols T. C., Kay M. A., Ehrhardt A. 2010; Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B. Mol Ther 18:1896–1906 [CrossRef]
     [Google Scholar]
  14. Jager L., Hausl M. A., Rauschhuber C., Wolf N. M., Kay M. A., Ehrhardt A. 2009; A rapid protocol for construction and production of high-capacity adenoviral vectors. Nat Protoc 4:547–564 [View Article][PubMed]
     [Google Scholar]
  15. Khare R., May S. M., Vetrini F., Weaver E. A., Palmer D., Rosewell A., Grove N., Ng P., Barry M. A. 2011; Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther 19:1254–1262 [CrossRef]
     [Google Scholar]
  16. Ma J., Duffy M. R., Deng L., Dakin R. S., Uil T., Custers J., Kelly S. M., McVey J. H., Nicklin S. A., Baker A. H. 2015; Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo . PLoS Pathog 11:e1004673 [View Article][PubMed]
     [Google Scholar]
  17. Mück-Häusl M., Solanki M., Zhang W., Ruzsics Z., Ehrhardt A. 2015; Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res 43:e50 [View Article][PubMed]
     [Google Scholar]
  18. Reddy V. S., Natchiar S. K., Stewart P. L., Nemerow G. R. 2010; Crystal structure of human adenovirus at 3.5 A resolution. Science 329:1071–1075 [View Article][PubMed]
     [Google Scholar]
  19. Roberts D. M., Nanda A., Havenga M. J., Abbink P., Lynch D. M., Ewald B. A., Liu J., Thorner A. R., Swanson P. E., other authors. 2006; Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239–243 [View Article][PubMed]
     [Google Scholar]
  20. Roy S., Shirley P. S., McClelland A., Kaleko M. 1998; Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 72:6875–6879[PubMed]
     [Google Scholar]
  21. Sprangers M. C., Lakhai W., Koudstaal W., Verhoeven M., Koel B. F., Vogels R., Goudsmit J., Havenga M. J., Kostense S. 2003; Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 41:5046–5052 [View Article][PubMed]
     [Google Scholar]
  22. Sumida S. M., Truitt D. M., Lemckert A. A., Vogels R., Custers J. H., Addo M. M., Lockman S., Peter T., Peyerl F. W., other authors. 2005; Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 174:7179–7185 [View Article][PubMed]
     [Google Scholar]
  23. Trotman L. C., Mosberger N., Fornerod M., Stidwill R. P., Greber U. F. 2001; Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat Cell Biol 3:1092–1100 [View Article][PubMed]
     [Google Scholar]
  24. Waddington S. N., McVey J. H., Bhella D., Parker A. L., Barker K., Atoda H., Pink R., Buckley S. M., Greig J. A., other authors. 2008; Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397–409 [View Article][PubMed]
     [Google Scholar]
  25. Youil R., Toner T. J., Su Q., Chen M., Tang A., Bett A. J., Casimiro D. 2002; Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13:311–320 [View Article][PubMed]
     [Google Scholar]
  26. Zhang W., Muck-Hausl M., Wang J., Sun C., Gebbing M., Miskey C., Ivics Z., Izsvak Z., Ehrhardt A. 2013; Integration profile and safety of an adenovirus hybrid-vector utilizing hyperactive sleeping beauty transposase for somatic integration. PLoS One 8:e75344 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000328
Loading
Adenovirus hexon modifications influence in vitro properties of pseudotyped human adenovirus type 5 vectors
J. Gen. Virol. 97, 160 (2016); https://doi.org/10.1099/jgv.0.000328
/content/journal/jgv/10.1099/jgv.0.000328
/content/journal/jgv/10.1099/jgv.0.000328
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error